Shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) have earned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $26.00.
Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lowered shares of Elanco Animal Health from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $28.00 to $24.00 in a report on Tuesday. Piper Sandler assumed coverage on shares of Elanco Animal Health in a report on Monday, July 11th. They issued a “neutral” rating and a $22.00 price target on the stock. The Goldman Sachs Group lowered shares of Elanco Animal Health from a “buy” rating to a “sell” rating and lowered their price target for the company from $32.00 to $19.00 in a report on Thursday, July 21st. Morgan Stanley reduced their target price on shares of Elanco Animal Health to $37.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. Finally, Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, June 24th.
Elanco Animal Health Trading Down 3.6 %
Shares of ELAN stock opened at $19.36 on Tuesday. Elanco Animal Health has a 1 year low of $18.64 and a 1 year high of $35.00. The firm’s fifty day simple moving average is $20.45 and its 200 day simple moving average is $23.73. The firm has a market capitalization of $9.18 billion, a P/E ratio of -55.31, a price-to-earnings-growth ratio of 2.00 and a beta of 0.79. The company has a current ratio of 2.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.84.
Insider Buying and Selling
In related news, Director R David Hoover purchased 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average price of $23.33 per share, for a total transaction of $233,300.00. Following the transaction, the director now directly owns 125,000 shares in the company, valued at $2,916,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Herold Advisors Inc. bought a new stake in Elanco Animal Health during the 1st quarter worth about $26,000. CKW Financial Group bought a new stake in Elanco Animal Health during the 4th quarter worth about $30,000. Tcwp LLC bought a new stake in Elanco Animal Health during the 1st quarter worth about $29,000. IndexIQ Advisors LLC bought a new stake in Elanco Animal Health during the 1st quarter worth about $32,000. Finally, Benjamin Edwards Inc. raised its holdings in Elanco Animal Health by 157.1% during the 4th quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company’s stock worth $40,000 after purchasing an additional 872 shares during the last quarter.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Skyworks Solutions Is Worth A Look At These Prices
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.